Eyegate pharmaceuticals inc (EYEG)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Collaboration Revenue

2,686

1,652

-

-

-

-

Collaboration Revenue

-

-

407

-

-

-

Collaboration Revenue

-

-

-

669

0

-

Operating Expenses:
Research and Development

5,389

8,055

10,330

8,422

2,717

531

General and Administrative

4,405

4,441

4,636

5,593

3,960

1,930

Total Operating Expenses

9,795

12,497

14,966

14,016

6,677

2,462

Other Income, Net:
Research & development tax credit

-

-

-

-

-

15

Interest Income

108

120

0

3

0

1

Extinguishment of research liability

-

-

-

-

-

240

Change in Fair Value of Warrant Liability

-

-

-

-

-223

-1,095

Interest Expense

0

1

1

0

1,934

441

Other Income, Net

-

-

-

-

0

0

Total Other Income, Net

107

119

-0

3

-1,710

910

Loss Before Income Tax Expense

-7,001

-10,725

-14,559

-13,343

-

-

Income Tax Expense

95

86

-1,341

0

-

-

Net (Loss) Income

-7,096

-10,811

-13,217

-

-

-

Net Loss

-

-

-

-13,343

-8,387

-1,551

Deemed Dividend on Preferred Stock

-

-

-

-

8,222

-

Net Loss per Common Share - Basic and Diluted

-

-

-

-0

5

222

Net Loss Attributable to Common Stockholders

-

-

-

-

-16,615

-1,773

Net Loss per Common Share- Basic and Diluted

-2.23

-4.57

-0.93

-

-2.70

-9.20

Weighted Average Shares Outstanding- Basic and Diluted

3,181

2,365

14,260

8,833

6,164

192

Net (Loss) Income

-7,096

-10,811

-

-

-

-

Net Loss

-

-

-

-13,343

-8,387

-1,551

Other Comprehensive (Loss) Income:
Foreign Currency Translation Adjustments

5

6

7

5

91

-

Comprehensive (Loss) Income

-7,091

-10,804

-13,210

-13,338

-8,296

-

Net Loss Attributable to Non-Controlling Interest

-

-

-

-0

5

222

Other Comprehensive Income Attributable to Non-Controlling Interests

-

-

-

-

-32

-

Comprehensive Income Attributable to Non-Controlling Interests

-

-

-

-

-27

-

Comprehensive Loss Attributable to Common Stockholders

-

-

-

-

-8,268

-